The article discusses the bullish investor sentiment towards the market, especially after the Fed's interest rate cut. It analyzes Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) as a top Russell 2000 stock, highlighting its potential in oncology therapies.